Celldex Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 29, 2021. Q4 figures are included below. Celldex is a clinical-stage biopharmaceutical company with no commercial product revenue; it develops antibody therapies for inflammatory diseases and cancer.
Business context and pipeline
- CDX-0159: Completed a Phase 1a healthy-volunteer study and began Phase 1b studies in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company planned a prurigo nodularis study and a subcutaneous formulation program for 2021.
- CDX-1140: Phase 1 dose escalation established a recommended dose of 1.5 mg/kg. Expansion and combination cohorts included pembrolizumab and pancreatic-cancer chemotherapy.
- CDX-527: Phase 1 study in advanced solid tumors began in August 2020; enrollment was ongoing.
- All programs were fully owned by Celldex at year-end. The company also performed contracted manufacturing and research services.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $7.4 million | $3.6 million |
| Research and development expense | $42.5 million | $42.7 million |
| Total operating expenses | $70.8 million | $58.6 million |
| Operating loss | $63.4 million | $55.0 million |
| Net loss | $59.8 million | $50.9 million |
| Basic and diluted loss per share | $2.02 | $3.51 |
| Net cash used in operating activities | $40.4 million | $46.4 million |
- Q4 2020: Revenue was $3.8 million, net loss was $21.9 million, and basic and diluted loss per share was $0.55.
- There were no product-sale revenues. Revenue came from development/licensing agreements, contracts and grants. Rockefeller University and Gilead Sciences together accounted for 85% of FY2020 revenue.
- Year-end liquidity: Cash and cash equivalents were $43.8 million and marketable securities were $150.6 million, totaling $194.4 million. Working capital was $183.6 million; total assets were $235.8 million.
- Management said year-end resources were expected to fund planned operations through 2023, while noting that cash milestone payments could affect this assessment. The financial-statement note separately states resources were sufficient for at least 12 months from issuance.
- Net cash provided by financing activities was $171.2 million, principally from a June public offering that generated $141.4 million net and ATM sales that generated $29.4 million net. Shares outstanding increased from 17.0 million to 39.6 million during 2020.
- Net cash used in investing activities was $98.2 million, primarily reflecting net purchases of marketable securities. The filing reports no off-balance-sheet arrangements. No material funded debt was outstanding at year-end; liabilities included operating leases and contingent consideration.
- No meaningful commercial gross margin was reported because Celldex had no product sales. The filing does not provide a clear product-sales margin measure.
Changes, outlook, and notable items
- Revenue more than doubled year over year, mainly due to a $1.8 million payment connected with the Rockefeller/Gilead transaction and increased contracted services. Management expected revenue to decrease over the following 12 months as product-development and licensing revenue declined.
- Net loss widened by $8.9 million, principally due to $18.0 million of non-cash intangible-asset impairment, partly offset by higher revenue and a $4.2 million gain from remeasurement of contingent consideration. The impairments comprised $14.5 million for the TAM program and $3.5 million for discontinued CDX-3379.
- Management expected operating losses to continue in 2021 and beyond and anticipated higher product-development expenses over the next 12 months as clinical-trial, contract-research and manufacturing activity increased. R&D spending was expected to remain a significant share of operating costs.
- In March 2021, after the reporting period, Celldex reported interim CIndU results: 8 of 10 evaluable patients had a complete response by provocation testing. The small, early-stage interim result is not conclusive evidence of efficacy. A severe infusion reaction involving brief loss of consciousness was reported in one of 15 treated patients; the patient recovered after treatment and observation.
- Potential Kolltan acquisition milestone payments were up to $107.5 million after certain milestones were abandoned. The company disputed the former stockholders’ representative’s objections concerning CDX-0158 and CDX-3379; litigation was ongoing, the outcome and potential loss were not estimable, and trial was scheduled for 2022. Payments could be made in cash or shares, creating liquidity or dilution risk.
- COVID-19 had not significantly disrupted trials or manufacturing to date, but the company continued to monitor risks to enrollment, sites, suppliers and timelines. Other material risks include clinical and regulatory failure, manufacturing and third-party dependence, competition, intellectual-property disputes, funding needs, and uncertain reimbursement and commercialization.
- Auditors issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- Whether clinical-trial enrollment, follow-up and results for CDX-0159, CDX-1140 and CDX-527 support the company’s development plans, including safety findings and the durability of reported responses.
- Whether the stated cash runway through 2023 remains achievable after operating spending, reduced expected revenue and any Kolltan milestone payments.
- The status and potential financial or dilution impact of the Kolltan milestone dispute, including whether CDX-0159 could trigger disputed payments.
- Whether the TAM impairment and out-licensing strategy, and any further program changes, lead to additional impairment charges or altered development priorities.
- Revenue concentration and the timing and renewal of Rockefeller/Gilead and other service arrangements, alongside the company’s expected revenue decline.
- Future share issuance and dilution, given the large 2020 equity raises, the remaining $50.0 million ATM capacity reported at year-end, and potential stock-settled milestones.